Literature DB >> 21159859

Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients.

Rui S Soares1, Rita Tendeiro, Russell B Foxall, António P Baptista, Rita Cavaleiro, Perpétua Gomes, Ricardo Camacho, Emília Valadas, Manuela Doroana, Margarida Lucas, Francisco Antunes, Rui M M Victorino, Ana E Sousa.   

Abstract

Viremia is significantly lower in HIV-2 than in HIV-1 infection, irrespective of disease stage. Nevertheless, the comparable proviral DNA burdens observed for these two infections indicate similar numbers of infected cells. Here we investigated this apparent paradox by assessing cell-associated viral replication. We found that untreated HIV-1-positive (HIV-1(+)) and HIV-2(+) individuals, matched for CD4 T cell depletion, exhibited similar gag mRNA levels, indicating that significant viral transcription is occurring in untreated HIV-2(+) patients, despite the reduced viremia (undetectable to 2.6 × 10(4) RNA copies/ml). However, tat mRNA transcripts were observed at significantly lower levels in HIV-2(+) patients, suggesting that the rate of de novo infection is decreased in these patients. Our data also reveal a direct relationship of gag and tat transcripts with CD4 and CD8 T cell activation, respectively. Antiretroviral therapy (ART)-treated HIV-2(+) patients showed persistent viral replication, irrespective of plasma viremia, possibly contributing to the emergence of drug resistance mutations, persistent hyperimmune activation, and poor CD4 T cell recovery that we observed with these individuals. In conclusion, we provide here evidence of significant ongoing viral replication in HIV-2(+) patients, further emphasizing the dichotomy between amount of plasma virus and cell-associated viral burden and stressing the need for antiretroviral trials and the definition of therapeutic guidelines for HIV-2 infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159859      PMCID: PMC3067805          DOI: 10.1128/JVI.01921-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

Authors:  F Damond; F Brun-Vezinet; S Matheron; G Peytavin; P Campa; S Pueyo; F Mammano; S Lastere; I Farfara; F Simon; G Chene; D Descamps
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

2.  Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection.

Authors:  N Berry; K Ariyoshi; S Jaffar; S Sabally; T Corrah; R Tedder; H Whittle
Journal:  J Hum Virol       Date:  1998 Nov-Dec

3.  Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.

Authors:  S J Popper; A D Sarr; K U Travers; A Guèye-Ndiaye; S Mboup; M E Essex; P J Kanki
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

4.  Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France.

Authors:  Philippe Colson; Mireille Henry; Natacha Tivoli; Hervé Gallais; Jean-Albert Gastaut; Jacques Moreau; Catherine Tamalet
Journal:  J Med Virol       Date:  2005-03       Impact factor: 2.327

5.  Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.

Authors:  Marchina E van der Ende; Jan M Prins; Kees Brinkman; Monique Keuter; Jan Veenstra; Sven A Danner; Hubert G M Niesters; Albert D M E Osterhaus; Martin Schutten
Journal:  AIDS       Date:  2003-07       Impact factor: 4.177

6.  Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay.

Authors:  P Gomes; N C Taveira; J M Pereira; F Antunes; M O Ferreira; M H Lourenço
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

7.  Human immunodeficiency virus type 2 infection associated with AIDS in West Africa.

Authors:  F Clavel; K Mansinho; S Chamaret; D Guetard; V Favier; J Nina; M O Santos-Ferreira; J L Champalimaud; L Montagnier
Journal:  N Engl J Med       Date:  1987-05-07       Impact factor: 91.245

8.  T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis.

Authors:  Jason M Brenchley; Brenna J Hill; David R Ambrozak; David A Price; Francisco J Guenaga; Joseph P Casazza; Janaki Kuruppu; Javaidia Yazdani; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.

Authors:  P Colson; M Henry; C Tourres; D Lozachmeur; H Gallais; J A Gastaut; J Moreau; C Tamalet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

10.  Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

Authors:  Myriam Witvrouw; Christophe Pannecouque; William M Switzer; Thomas M Folks; Erik De Clercq; Walid Heneine
Journal:  Antivir Ther       Date:  2004-02
View more
  21 in total

Review 1.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A.

Authors:  Nuno R Faria; Ioannis Hodges-Mameletzis; Joana C Silva; Berta Rodés; Smit Erasmus; Stefania Paolucci; Jean Ruelle; Danuta Pieniazek; Nuno Taveira; Ana Treviño; Maria F Gonçalves; Sabelle Jallow; Li Xu; Ricardo J Camacho; Vincent Soriano; Patrick Goubau; João D de Sousa; Anne-Mieke Vandamme; Marc A Suchard; Philippe Lemey
Journal:  J Gen Virol       Date:  2011-12-21       Impact factor: 3.891

3.  miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication.

Authors:  Andreia J Amaral; Jorge Andrade; Russell B Foxall; Paula Matoso; Ana M Matos; Rui S Soares; Cheila Rocha; Christian G Ramos; Rita Tendeiro; Ana Serra-Caetano; José A Guerra-Assunção; Mariana Santa-Marta; João Gonçalves; Margarida Gama-Carvalho; Ana E Sousa
Journal:  EMBO J       Date:  2016-12-19       Impact factor: 11.598

4.  Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes.

Authors:  Helena Nunes-Cabaço; Paula Matoso; Russell B Foxall; Rita Tendeiro; Ana R Pires; Tânia Carvalho; Ana I Pinheiro; Rui S Soares; Ana E Sousa
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

5.  HIV-2 infection is associated with preserved GALT homeostasis and epithelial integrity despite ongoing mucosal viral replication.

Authors:  S M Fernandes; A R Pires; P Matoso; C Ferreira; H Nunes-Cabaço; L Correia; E Valadas; J Poças; P Pacheco; H Veiga-Fernandes; R B Foxall; A E Sousa
Journal:  Mucosal Immunol       Date:  2017-05-17       Impact factor: 7.313

6.  Evidence for a different susceptibility of primate lentiviruses to type I interferons.

Authors:  Stéphanie Cordeil; Xuan-Nhi Nguyen; Gregory Berger; Stéphanie Durand; Michelle Ainouze; Andrea Cimarelli
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

7.  Novel inhibitors of human immunodeficiency virus type 2 infectivity.

Authors:  Lauren B Beach; Jonathan M Rawson; Baek Kim; Steven E Patterson; Louis M Mansky
Journal:  J Gen Virol       Date:  2014-08-07       Impact factor: 3.891

8.  Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy.

Authors:  Keith Shults; Leanne Flye-Blakemore; Bruce K Patterson; Tarek Elbeik
Journal:  Future Virol       Date:  2012-08       Impact factor: 1.831

Review 9.  Delayed disease progression in HIV-2: the importance of TRIM5α and the retroviral capsid.

Authors:  M T Boswell; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2019-03-21       Impact factor: 4.330

Review 10.  Cell-associated HIV RNA: a dynamic biomarker of viral persistence.

Authors:  Alexander O Pasternak; Vladimir V Lukashov; Ben Berkhout
Journal:  Retrovirology       Date:  2013-04-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.